Your browser is no longer supported. Please, upgrade your browser.
Settings
AIMT Aimmune Therapeutics, Inc. daily Stock Chart
AIMT [NASD]
Aimmune Therapeutics, Inc.
Index- P/E- EPS (ttm)-2.07 Insider Own1.00% Shs Outstand59.12M Perf Week0.44%
Market Cap1.87B Forward P/E- EPS next Y-2.51 Insider Trans-35.10% Shs Float47.68M Perf Month-0.94%
Income-104.40M PEG- EPS next Q-0.71 Inst Own74.00% Short Float9.73% Perf Quarter-18.69%
Sales- P/S- EPS this Y-9.60% Inst Trans1.84% Short Ratio4.34 Perf Half Y21.56%
Book/sh3.50 P/B9.04 EPS next Y16.60% ROA-54.00% Target Price60.00 Perf Year60.97%
Cash/sh3.09 P/C10.25 EPS next 5Y34.60% ROE-59.00% 52W Range15.97 - 42.00 Perf YTD-16.37%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-24.69% Beta-
Dividend %- Quick Ratio7.10 Sales past 5Y- Gross Margin- 52W Low98.06% ATR1.45
Employees131 Current Ratio7.10 Sales Q/Q- Oper. Margin- RSI (14)52.06 Volatility4.24% 5.35%
OptionableYes Debt/Eq0.00 EPS Q/Q49.10% Profit Margin- Rel Volume0.25 Prev Close31.33
ShortableYes LT Debt/Eq0.00 EarningsMar 21 BMO Payout- Avg Volume1.07M Price31.63
Recom1.80 SMA202.93% SMA50-3.56% SMA2006.39% Volume268,670 Change0.96%
Feb-07-18Initiated RBC Capital Mkts Outperform $55
Dec-21-17Initiated Robert W. Baird Outperform $64
Nov-20-17Initiated ROTH Capital Buy
Sep-26-16Initiated JMP Securities Mkt Outperform
Mar-01-16Initiated Wedbush Outperform $42
Nov-17-15Reiterated Piper Jaffray Overweight $35 → $38
Aug-31-15Initiated Piper Jaffray Overweight $35
Aug-31-15Initiated Credit Suisse Outperform $44
Aug-31-15Initiated BofA/Merrill Buy $36
Apr-19-18 08:15AM  Market Trends Toward New Normal in Genuine Parts, Energizer, Arthur J. Gallagher, Aimmune Therapeutics, Roku, and Premier Emerging Consolidated Expectations, Analyst Ratings GlobeNewswire
Apr-04-18 09:02AM  April Stocks Insiders Just Bought Simply Wall St.
Apr-02-18 06:52PM  Is This Why AnaptysBio Inc. Fell on Monday? Motley Fool -6.85%
Mar-27-18 08:36AM  Protecting children from severe peanut allergies Fox Business Videos
Mar-26-18 05:34PM  After-hours buzz: RHT, ANAB & more CNBC
Mar-12-18 08:09AM  Aimmune Therapeutics reports 4Q loss Associated Press
08:00AM  Aimmune Therapeutics Announces Fourth Quarter and Full Year 2017 Financial Results Business Wire
Mar-07-18 08:00AM  Aimmune Therapeutics to Participate in Four Investor Conferences in March Business Wire
Mar-05-18 10:08AM  Company News For Mar 5, 2018 Zacks +5.58%
Mar-04-18 02:00PM  Aimmune Therapeutics Presents Results From the Positive, Pivotal Phase 3 PALISADE Trial of AR101 for Peanut Allergy at AAAAI-WAO Business Wire
Mar-02-18 04:01PM  Aimmune Therapeutics Announces Exercise in Full of Underwriters Option to Purchase Additional Shares of Common Stock Business Wire
12:58PM  Peanut Allergy-Focused Biotech May Strike Magic in Orlando Bloomberg
Feb-27-18 03:38PM  Insiders Are Frantically Buying Up These Cheap Stocks Insider Monkey +5.18%
07:00AM  Aimmune Therapeutics to Host Analyst and Investor Event Following Oral Late-Breaking Presentation of Phase 3 PALISADE Results on Sunday, March 4, at the AAAAI-WAO Joint Congress in Orlando Business Wire
Feb-26-18 04:01PM  Aimmune Therapeutics Announces Closing of Public Offering of Common Stock Business Wire -7.98%
Feb-22-18 07:40AM  Wired News Aimmune Therapeutics Peanut Allergy Drug AR101 Met Primary Endpoint in Pivotal Phase-3 Clinical Trial ACCESSWIRE
Feb-21-18 07:28PM  Aimmune Therapeutics Announces Pricing of Public Offering of Common Stock Business Wire -7.87%
12:53PM  Aimmune Therapeutics Is Moving on Allergy Data GuruFocus.com
12:00AM  [$$] A new peanut allergy drug could force a change of behaviour Financial Times
Feb-20-18 04:16PM  Aimmune Therapeutics Announces Proposed Public Offering of Common Stock Business Wire -6.02%
09:01AM  Aimmune shares surge 10% on positive late-stage trial results for peanut allergy drug MarketWatch
07:49AM  [$$] Aimmunes peanut allergy drug succeeds in late stage clinical trial Financial Times
07:24AM  Aimmune's peanut allergy drug meets main goal of key study Reuters
07:06AM  Aimmune's peanut allergy drug meets main goal of key study Reuters
07:00AM  Aimmune Therapeutics Pivotal Phase 3 PALISADE Trial of AR101 Meets Primary Endpoint in Patients With Peanut Allergy Business Wire
01:23AM  [$$] Peanut allergy drug nears approval after clinical trial success Financial Times
Feb-14-18 01:18PM  Why DBV Technologies Jumped Higher Today Motley Fool
08:00AM  Aimmune Therapeutics Expands Scientific Advisory Board With Appointments of George du Toit, M.B., B.Ch., and Wayne Shreffler, M.D., Ph.D. Business Wire
Feb-12-18 08:15AM  Aimmune Therapeutics Announces Presentations at 2018 AAAAI-WAO Joint Congress Business Wire
Feb-08-18 08:15AM  Report: Exploring Fundamental Drivers Behind Stericycle, Hemisphere Media Group, Expedia, Olin, Aimmune Therapeutics, and Waste Management New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire
Jan-13-18 10:00AM  How Trading Notes Can Increase Your Profits TheStreet.com
Jan-10-18 08:00AM  Aimmune Therapeutics Broadens and Extends Supply Agreement With Golden Peanut and Tree Nuts for AR101 for Peanut Allergy Business Wire
Jan-08-18 08:00AM  Aimmune Therapeutics Announces 2018 Outlook, Including Upcoming Data from Pivotal Phase 3 PALISADE Trial of AR101 for Peanut Allergy Business Wire
Jan-03-18 08:00AM  Aimmune Therapeutics to Present at the 36th Annual J.P. Morgan Healthcare Conference Business Wire
Dec-13-17 11:18AM  Moore Loss Won't Stop Tax Bill; Bitcoin Plays Are Bubbling TheStreet.com +5.21%
Dec-07-17 08:00AM  Aimmune Therapeutics to Participate in the BMO Capital Markets 2017 Prescriptions for Success Healthcare Conference on December 14 Business Wire
Nov-30-17 03:42PM  Aimmune Therapeutics, Inc. Fundamental Analysis : November 30, 2017 Capital Cube +6.32%
Nov-20-17 08:00AM  Aimmune Therapeutics to Host Investor Symposium on Peanut Allergy Treatment with Leading Expert Allergists on Friday, December 1 Business Wire
07:35AM  Report: Developing Opportunities within UGI, Party City Holdco, Old Dominion Freight Line, Olin, Aimmune Therapeutics, and Waste Management Future Expectations, Projections Moving into 2018 GlobeNewswire
Nov-06-17 08:37AM  Aimmune Therapeutics reports 3Q loss Associated Press
08:30AM  Aimmune Therapeutics Announces Third Quarter 2017 Financial Results and Planned Retirement of CEO by the End of 2018 Business Wire
Nov-01-17 08:00AM  Aimmune Therapeutics to Participate in Four Investor Conferences in November Business Wire
Oct-31-17 08:30AM  Aimmune Therapeutics Announces Publication in The Journal of Allergy and Clinical Immunology: In Practice of Positive AR101 Data from ARC001 Phase 2 Clinical Trial Business Wire
Oct-23-17 01:46PM  DBV Technologies Pain is Aimmune Therapeutics Incs (AIMT) Gain SmarterAnalyst +28.37%
01:27PM  Why DBV Technologies SA Plummeted and Aimmune Therapeutics Inc Skyrocketed Today Motley Fool
09:15AM  DBV Shares Fall After Phase 3 Data on Peanut Allergy Treatment -- Biotech Movers TheStreet.com
Oct-20-17 06:17PM  DBV Technologies Plunges By Half On Allergy Drug Trial's Failure Investor's Business Daily
Oct-19-17 08:00AM  Aimmune Therapeutics to Present Data on Peanut Allergy at ACAAI and PAAM Medical Meetings Business Wire
Oct-18-17 10:54AM  [$$] Aimmune, DBV: Fighting Over More Than Peanuts Barrons.com
Oct-16-17 09:19AM  Aimmune teams with Regeneron, Sanofi on peanut allergy drug Reuters
07:30AM  Aimmune Therapeutics Announces Clinical Collaboration to Study AR101 with Regeneron and Sanofis Dupilumab for Peanut Allergy Business Wire
07:20AM  Drugmakers Are Planning to Start a Phase 2 Trial to Cure Peanut Allergy Bloomberg
Oct-09-17 08:38AM  Is the Options Market Predicting a Spike in Aimmune Therapeutics (AIMT) Stock? Zacks
Sep-26-17 08:43AM  Aimmune Therapeutics (AIMT) in Focus: Stock Moves 6.3% Higher Zacks
Sep-06-17 08:00AM  Aimmune Therapeutics to Participate in Three Investor Conferences in September Business Wire
Aug-09-17 08:00AM  Aimmune Therapeutics to Present at the 2017 Wedbush PacGrow Healthcare Conference on Wednesday, August 16th Business Wire -7.50%
Aug-08-17 10:30PM  Aimmune Therapeutics reports 2Q loss Associated Press
04:01PM  Aimmune Therapeutics Announces Second Quarter 2017 Financial Results Business Wire
08:00AM  Aimmune Therapeutics Investigational Treatment for Peanut Allergy Featured in Science Translational Medicine Publication on Discovery of New TH2 Cell Subset Specific to Allergy Business Wire
Jul-10-17 08:20AM  AVEO Pharmaceuticals (AVEO) Worth a Look: Stock Up 14.8% Zacks
Jul-05-17 08:00AM  Aimmune Therapeutics Enrolls First Patient in ARTEMIS (ARC010) European Phase 3 Clinical Trial of AR101 for the Treatment of Peanut Allergy Business Wire
Jun-30-17 06:04AM  Aimmune Therapeutics (AIMT) Shares March Higher, Can It Continue? Zacks
Jun-21-17 08:20AM  Dynavax Technologies (DVAX) Catches Eye: Stock Gains 6.6% Zacks
Jun-20-17 06:30AM  Aimmune Therapeutics Presents European Phase 3 PALISADE Screening Data at 2017 European Academy of Allergy and Clinical Immunology (EAACI) Congress Business Wire
Jun-15-17 08:00AM  Aimmune Therapeutics to Present Data on Peanut Allergy in Europe at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2017 Business Wire
Jun-12-17 04:01PM  Aimmune Therapeutics Reports on Up-Dosing in Its Ongoing Phase 3 PALISADE Trial of AR101 for Peanut Allergy Business Wire
Jun-08-17 08:00AM  Aimmune Therapeutics to Present at the Goldman Sachs 38th Annual Global Healthcare Conference on Thursday, June 15th Business Wire
07:50AM  Clearwater project targets peanut allergies American City Business Journals
Jun-07-17 08:00AM  Aimmune Therapeutics Cuts Ribbon on Commercial Manufacturing Facility to Support Potential Launch of Treatment for Peanut Allergy Business Wire
May-15-17 03:16PM  Why These Drug Stocks May Surge Investopedia
May-11-17 08:00AM  Aimmune Therapeutics Enrolls First Patient in RAMSES (ARC007), a Phase 3 Clinical Trial of AR101 for the Treatment of Peanut Allergy Business Wire
May-09-17 08:00AM  Aimmune Therapeutics to Present at the Bank of America Merrill Lynch Healthcare Conference on Tuesday, May 16 Business Wire
May-08-17 04:05PM  Aimmune Therapeutics reports 1Q loss Associated Press
04:01PM  Aimmune Therapeutics Announces First Quarter 2017 Financial Results Business Wire
May-01-17 04:11PM  Biotechs Cruise On 6-Day Upswing Despite Price Target Cuts For This Duo Investor's Business Daily
Apr-13-17 06:00AM  Aimmune Therapeutics Appoints Eric Bjerkholt as Chief Financial Officer Business Wire
Apr-11-17 08:43AM  Should You Get Rid of Aimmune Therapeutics (AIMT) Now? Zacks
Mar-21-17 01:04PM  AIMMUNE THERAPEUTICS, INC. Financials
Mar-16-17 10:07AM  Edited Transcript of AIMT earnings conference call or presentation 15-Mar-17 12:00pm GMT Thomson Reuters StreetEvents
Mar-15-17 08:00AM  Aimmune Therapeutics Inc Earnings Call scheduled for 8:00 am ET today
07:17AM  AIMMUNE THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements an
07:07AM  Q4 2016 Aimmune Therapeutics Inc Earnings Release - Before Market Open
07:06AM  Aimmune Therapeutics reports 4Q loss Associated Press
07:00AM  Aimmune Therapeutics Announces Fourth Quarter and Full Year 2016 Financial Results Business Wire
Mar-08-17 08:00AM  Aimmune Therapeutics to Release Fourth Quarter and Full Year 2016 Financial Results on Wednesday, March 15, 2017 Business Wire
Mar-06-17 09:45AM  Aimmune Therapeutics Presents Clinical Data on Phase 3 Screening and Phase 2 Adherence for AR101 for Peanut Allergy at the 2017 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting Business Wire
Mar-01-17 08:00AM  Aimmune Therapeutics to Participate in Two Upcoming Investor Conferences in March Business Wire
Feb-27-17 08:00AM  Aimmune Therapeutics to Present AR101 Clinical Data in Peanut Allergy at the 2017 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting Business Wire +7.13%
Feb-16-17 05:00PM  Aimmune Therapeutics Inc Conference Call to Discuss The Announced AR101 Program Updates scheduled for 5:00 pm ET today
04:30PM  AIMMUNE THERAPEUTICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
04:01PM  Aimmune Therapeutics Provides Update on Ongoing AR101 Phase 3 Program for Peanut Allergy Based on FDA Feedback Business Wire
Feb-03-17 05:21PM  AIMMUNE THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Ex +5.40%
Jan-09-17 09:03AM  AIMMUNE THERAPEUTICS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
Jan-04-17 08:00AM  Aimmune Therapeutics to Present at the 35th Annual J.P. Morgan Healthcare Conference Business Wire
Dec-14-16 05:03PM  AIMMUNE THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers
Dec-11-16 07:26AM  Hedge Funds Arent Crazy About Aimmune Therapeutics Inc (AIMT) Anymore at Insider Monkey
Dec-01-16 07:00AM  Aimmune Therapeutics Appoints Scientific Advisory Board of World-Renowned Food Allergy Experts Business Wire
Nov-30-16 10:05AM  Aimmune Closes Enrolment in Phase III Peanut Allergy Study -6.97%
Nov-28-16 02:14PM  Aimmune Therapeutics, Inc. :AIMT-US: Earnings Analysis: Q3, 2016 By the Numbers : November 28, 2016
08:01AM  Aimmune Therapeutics Completes Global Enrollment of Phase 3 PALISADE Trial of AR101 for the Treatment of Peanut Allergy Business Wire
Aimmune Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies. Its lead Characterized Oral Desensitization ImmunoTherapy product candidate is AR101, an investigational biologic for the treatment of patients with peanut allergy. The company has strategic collaboration with an affiliate of Nestle Health Science US Holdings, Inc. for the advancement of food allergy therapeutics. The company was formerly known as Allergen Research Corporation and changed its name to Aimmune Therapeutics, Inc. in May 2015. Aimmune Therapeutics, Inc. was founded in 2011 and is headquartered in Brisbane, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Sheehy Douglas T.See RemarksMar 05Option Exercise16.513,52358,14834,375Mar 06 08:40 PM
Sheehy Douglas T.See RemarksMar 05Sale36.523,523128,66732,500Mar 06 08:40 PM
Rozenman Mary M.See RemarksMar 01Option Exercise3.021,8075,4611,936Mar 05 04:05 PM
Rozenman Mary M.See RemarksMar 01Sale33.101,80759,812129Mar 05 04:05 PM
BJERKHOLT ERICChief Financial OfficerFeb 26Buy32.003,125100,0008,125Feb 26 04:05 PM
FALBERG KATHRYN EDirectorFeb 26Buy32.0030,000960,000124,894Feb 26 04:05 PM
Iwicki Mark TDirectorFeb 26Buy32.009,375300,00029,375Feb 26 04:05 PM
Tammenoms Bakker Juliet10% OwnerFeb 22Buy32.009,375300,00016,651Feb 26 04:25 PM
ENRIGHT PATRICK GDirectorFeb 22Buy32.0015,593498,97622,869Feb 26 04:22 PM
Sheehy Douglas T.See RemarksFeb 05Option Exercise12.951,64821,3421,648Feb 07 04:06 PM
Sheehy Douglas T.See RemarksFeb 05Sale35.871,64859,1140Feb 07 04:06 PM
Rozenman Mary M.See RemarksFeb 01Option Exercise3.026,59219,9216,721Feb 05 04:05 PM
Rozenman Mary M.See RemarksFeb 01Sale35.366,592233,088129Feb 05 04:05 PM
Sheehy Douglas T.See RemarksJan 24Option Exercise19.631,87536,8061,875Jan 26 05:32 PM
Sheehy Douglas T.See RemarksJan 24Sale38.151,87571,5310Jan 26 05:32 PM
ADELMAN DANIEL C MDChief Medical OfficerJan 16Option Exercise11.459,933113,7339,933Jan 16 06:05 PM
ADELMAN DANIEL C MDChief Medical OfficerJan 16Sale40.009,933397,3200Jan 16 06:05 PM
ADELMAN DANIEL C MDChief Medical OfficerJan 12Option Exercise11.4526,784306,67726,784Jan 16 06:05 PM
ADELMAN DANIEL C MDChief Medical OfficerJan 12Sale40.0026,7841,071,3600Jan 16 06:05 PM
Sheehy Douglas T.See RemarksJan 04Option Exercise12.951,64821,3421,648Jan 08 04:07 PM
Sheehy Douglas T.See RemarksJan 04Sale37.331,64861,5200Jan 08 04:07 PM
Rozenman Mary M.See RemarksJan 02Option Exercise3.026,59119,9186,720Jan 04 04:05 PM
Barrowcliffe Susan E.General Manager, EuropeJan 02Option Exercise3.0275,000226,65075,000Jan 04 04:05 PM
Barrowcliffe Susan E.General Manager, EuropeJan 02Sale37.1475,0002,785,1900Jan 04 04:05 PM
Rozenman Mary M.See RemarksJan 02Sale37.116,591244,590129Jan 04 04:05 PM
ADELMAN DANIEL C MDChief Medical OfficerDec 27Option Exercise11.453,28337,5903,283Dec 29 05:26 PM
ADELMAN DANIEL C MDChief Medical OfficerDec 27Sale40.003,283131,3200Dec 29 05:26 PM
Sheehy Douglas T.See RemarksDec 26Option Exercise19.631,87536,8061,875Dec 28 05:43 PM
Rozenman Mary M.See RemarksDec 26Option Exercise3.0275,010226,68075,139Dec 28 05:45 PM
Rozenman Mary M.See RemarksDec 26Sale38.8875,0102,916,086129Dec 28 05:45 PM
Sheehy Douglas T.See RemarksDec 26Sale39.441,87573,9500Dec 28 05:43 PM
Sheehy Douglas T.See RemarksDec 04Option Exercise12.951,90624,6831,906Dec 06 04:05 PM
Sheehy Douglas T.See RemarksDec 04Sale38.661,90673,6860Dec 06 04:05 PM
Sheehy Douglas T.See RemarksNov 30Option Exercise19.633,75073,6133,750Dec 04 04:05 PM
Sheehy Douglas T.See RemarksNov 30Sale37.003,750138,7500Dec 04 04:05 PM
Sheehy Douglas T.See RemarksNov 09Option Exercise12.951,90524,6701,905Nov 13 05:26 PM
Sheehy Douglas T.See RemarksNov 09Sale33.001,90562,8650Nov 13 05:26 PM
ADELMAN DANIEL C MDChief Medical OfficerOct 23Option Exercise11.4510,000114,50010,000Oct 25 04:05 PM
Sheehy Douglas T.See RemarksOct 23Option Exercise14.8047,425701,82934,300Oct 25 04:05 PM
Sheehy Douglas T.See RemarksOct 23Sale34.4447,4251,633,5140Oct 25 04:05 PM
ADELMAN DANIEL C MDChief Medical OfficerOct 23Sale34.0610,000340,6100Oct 25 04:05 PM
DILLY STEPHEN GEORGESee RemarksOct 23Sale33.55100,0003,354,538315,308Oct 25 04:05 PM
DILLY STEPHEN GEORGEPresident and CEOOct 16Sale26.241,15430,279415,308Oct 18 07:59 PM
DILLY STEPHEN GEORGEPresident and CEOOct 06Sale26.314,047106,468416,462Oct 06 06:02 PM
DILLY STEPHEN GEORGEPresident and CEOOct 05Sale26.2414,689385,495420,509Oct 06 06:02 PM
DILLY STEPHEN GEORGEPresident and CEOOct 04Sale26.2380,1102,101,353435,198Oct 06 06:02 PM
Barrowcliffe Susan E.General Manager, EuropeSep 25Option Exercise3.0220,00060,44020,000Sep 27 04:05 PM
ADELMAN DANIEL C MDChief Medical OfficerSep 25Option Exercise11.4510,000114,50010,000Sep 27 04:06 PM
ADELMAN DANIEL C MDChief Medical OfficerSep 25Sale25.0010,000250,0000Sep 27 04:06 PM
Barrowcliffe Susan E.General Manager, EuropeSep 25Sale25.0020,000500,0000Sep 27 04:05 PM
DILLY STEPHEN GEORGEPresident and CEOSep 25Sale25.01100,0002,500,790515,308Sep 27 04:05 PM
Rozenman Mary M.See RemarksSep 07Option Exercise3.0230,00090,66030,129Sep 11 05:17 PM
Rozenman Mary M.See RemarksSep 07Sale22.5030,000675,000129Sep 11 05:17 PM
Barrowcliffe Susan E.General Manager, EuropeSep 06Option Exercise3.0215,16745,83515,167Sep 07 04:05 PM
Barrowcliffe Susan E.General Manager, EuropeSep 06Sale22.0015,167333,7090Sep 07 04:05 PM
Barrowcliffe Susan E.General Manager, EuropeSep 05Option Exercise3.023,2239,7403,223Sep 07 04:05 PM
Barrowcliffe Susan E.General Manager, EuropeSep 05Sale22.003,22370,9060Sep 07 04:05 PM
Barrowcliffe Susan E.General Manager, EuropeJul 27Option Exercise3.025001,511500Jul 31 05:50 PM
Barrowcliffe Susan E.General Manager, EuropeJul 27Sale22.0050011,0000Jul 31 05:50 PM
DILLY STEPHEN GEORGEPresident and CEOJul 26Sale21.4650,0001,073,110615,308Jul 28 04:31 PM
Barrowcliffe Susan E.General Manager, EuropeJul 25Option Exercise3.024,65014,0524,650Jul 25 06:35 PM
Barrowcliffe Susan E.General Manager, EuropeJul 25Sale22.004,650102,3000Jul 25 06:35 PM
Barrowcliffe Susan E.General Manager, EuropeJul 24Option Exercise3.025001,511500Jul 25 06:35 PM
Barrowcliffe Susan E.General Manager, EuropeJul 24Sale22.0050011,0000Jul 25 06:35 PM
Barrowcliffe Susan E.General Manager, EuropeJul 21Option Exercise3.029602,901960Jul 25 06:35 PM
Barrowcliffe Susan E.General Manager, EuropeJul 21Sale22.0096021,1200Jul 25 06:35 PM
Sheehy Douglas T.See RemarksJul 21Sale21.667,460161,5580Jul 21 07:05 PM
Rozenman Mary M.See RemarksJul 17Option Exercise3.02300907429Jul 17 04:31 PM
Rozenman Mary M.See RemarksJul 17Sale21.383006,414129Jul 17 04:31 PM
Rozenman Mary M.See RemarksJul 14Option Exercise3.025,66617,1235,795Jul 17 04:31 PM
Rozenman Mary M.See RemarksJul 14Sale21.395,666121,175129Jul 17 04:31 PM
Rozenman Mary M.See RemarksJul 13Option Exercise3.028,97427,1199,103Jul 17 04:31 PM
Rozenman Mary M.See RemarksJul 13Sale21.478,974192,658129Jul 17 04:31 PM
Rozenman Mary M.See RemarksJul 05Option Exercise3.0215,06045,51115,189Jul 06 05:01 PM
Rozenman Mary M.See RemarksJul 05Sale21.4015,060322,212129Jul 06 05:01 PM
Barrowcliffe Susan E.General Manager, EuropeJul 03Option Exercise3.0215,00045,33015,000Jul 06 04:05 PM
Rozenman Mary M.See RemarksJul 03Option Exercise3.0230,00090,66030,129Jul 06 05:01 PM
Rozenman Mary M.See RemarksJul 03Sale20.5730,000617,178129Jul 06 05:01 PM
Barrowcliffe Susan E.General Manager, EuropeJul 03Sale20.2615,000303,9110Jul 06 04:05 PM
DILLY STEPHEN GEORGEPresident and CEOJun 23Sale20.2149,400998,591665,308Jun 27 04:06 PM
BJERKHOLT ERICChief Financial OfficerMay 12Buy19.845,00099,2105,000May 15 04:49 PM
DILLY STEPHEN GEORGESee RemarksMay 10Sale20.1560012,090714,708May 12 04:07 PM